Iacopo Chiodini1. 1. Department of Medical Sciences, University of Milan, Endocrinology and Diabetology Unit, Fondazione Ospedale Maggiore Policlinico, Istituto di Ricovero e Cura a Carattere Scientifico, Pad. Granelli, Via F. Sforza 35, 20122 Milan, Italy. iacopo.chiodini@email.it
Abstract
CONTEXT: Subclinical hypercortisolism (SH) is a condition of biochemical cortisol excess without the classical signs or symptoms of overt hypercortisolism. It is thought to be present in the 5-30% of patients with incidentally discovered adrenal mass (adrenal incidentalomas), which in turn are found in 4-7% of the adult population. Therefore, SH has been suggested to be present in 0.2-2.0% of the adult population. Some studies suggested that this condition is present in 1-10% of patients with diabetes or established osteoporosis. The present manuscript reviews the literature on diagnostic procedures and the metabolic effect of the recovery from SH. EVIDENCE ACQUISITION: A PubMed search was used to identify the available studies. The most relevant studies from 1992 to November 2010 have been included in the review. EVIDENCE SYNTHESIS: The available data suggest that SH may be associated with chronic complications, such as hypertension, diabetes mellitus, overweight/obesity, and osteoporosis. The available intervention studies suggest that the recovery from SH may lead to the improvement of hypertension and diabetes mellitus. A retrospective study suggests that this beneficial effect could be predicted before surgery. CONCLUSIONS: SH is suggested to be associated with some chronic complications of overt cortisol excess. Recovery from this condition seems to improve these complications. However, a large, prospective, randomized study is needed to confirm this hypothesis and to establish the best diagnostic approach to identify patients with adrenal incidentalomas who can benefit from surgery.
CONTEXT: Subclinical hypercortisolism (SH) is a condition of biochemical cortisol excess without the classical signs or symptoms of overt hypercortisolism. It is thought to be present in the 5-30% of patients with incidentally discovered adrenal mass (adrenal incidentalomas), which in turn are found in 4-7% of the adult population. Therefore, SH has been suggested to be present in 0.2-2.0% of the adult population. Some studies suggested that this condition is present in 1-10% of patients with diabetes or established osteoporosis. The present manuscript reviews the literature on diagnostic procedures and the metabolic effect of the recovery from SH. EVIDENCE ACQUISITION: A PubMed search was used to identify the available studies. The most relevant studies from 1992 to November 2010 have been included in the review. EVIDENCE SYNTHESIS: The available data suggest that SH may be associated with chronic complications, such as hypertension, diabetes mellitus, overweight/obesity, and osteoporosis. The available intervention studies suggest that the recovery from SH may lead to the improvement of hypertension and diabetes mellitus. A retrospective study suggests that this beneficial effect could be predicted before surgery. CONCLUSIONS: SH is suggested to be associated with some chronic complications of overt cortisol excess. Recovery from this condition seems to improve these complications. However, a large, prospective, randomized study is needed to confirm this hypothesis and to establish the best diagnostic approach to identify patients with adrenal incidentalomas who can benefit from surgery.
Authors: Alessandro Prete; Rosa Maria Paragliola; Filomena Bottiglieri; Carlo Antonio Rota; Alfredo Pontecorvi; Roberto Salvatori; Salvatore Maria Corsello Journal: Endocrine Date: 2016-07-09 Impact factor: 3.633
Authors: F Pugliese; A S Salcuni; C Battista; V Carnevale; G Guglielmi; C Columbu; F Velluzzi; L Giovanelli; C Eller-Vainicher; A Scillitani; I Chiodini Journal: Endocrine Date: 2021-01-23 Impact factor: 3.633
Authors: A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo Journal: J Endocrinol Invest Date: 2015-07-14 Impact factor: 4.256
Authors: Marta Araujo-Castro; Pablo Valderrábano; Héctor F Escobar-Morreale; Felicia A Hanzu; Gregori Casals Journal: Endocrine Date: 2020-11-21 Impact factor: 3.633